The funding round was led by Firstime Ventures, a leading sustainability and health venture capital fund from Israel.
BAIBYS™ Fertility is pleased to announce the successful completion of its Round A funding. The funding round was led by Firstime Ventures, a leading sustainability and health venture capital fund from Israel.
As part of the investment agreement, Keren Kopilov, Partner at Firstime, will be joining BAIBYS’ Board of Directors. This funding round also saw the participation of past investors, demonstrating their continued endorsement of the company and technology.
The company is now building its flagship product, an autonomous AI and micro-robotics-based system for sperm selection for IVF, conducting clinical studies, and completing the regulatory procedures. Supported by this funding, the company looks forward to bringing its patented ART (Artificial Reproductive Technology) to the IVF market and improving the lives of those facing infertility.
BAIBYS’ AI and robotics-based autonomous sperm selection solution is fully automated and is designed to be objective, consistent, fast, and more accurate than current manual methods. This is important as abnormal spermatozoa generally have a lower fertilizing potential depending on the types of anomalies and may also have abnormal DNA. It intends to solve challenges of the existing manual sperm selection carried out by embryologists, as these current practices require extensive training, are expensive, time-consuming as well as subjective and less consistent.
In addition to the successful investment round, BAIBYS™ is proud to have been selected out of numerous companies as one of the top 12 finalists in the Innovation Showcase at the Reproductive Health Innovation Summit. The Women’s Health Innovation Series summit will take place in Boston, MA on February 15-16, 2023.